Irf2-KO Mouse
Common Name
Irf2-KO
제품 ID
S-KO-18938
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-16363-Irf2-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Irf2-KO Mouse (카탈로그 번호 S-KO-18938)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Irf2-KO
품종 계통계통 ID
KOCMP-16363-Irf2-B6J-VB
유전자명
제품 ID
S-KO-18938
유전자 별칭
Irf-2, 9830146E22Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 8
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000034041
NCBI 전사체 ID
NM_008391
타겟 영역
Exon 3
유효 영역 크기
~1.1 kb
유전자 연구 개요
Irf2, or interferon regulatory factor 2, is a transcription factor belonging to the IRF family. It plays diverse roles in multiple biological processes. It is involved in cytokine signaling, cell growth regulation, and hematopoietic development [4]. In the immune system, Irf2 is associated with interferon-mediated signaling pathways, which are crucial for immune activation and suppression [2,6].
In colorectal cancer, oncogenic KRASG12D (KRAS∗) represses Irf2 expression. This repression leads to high CXCL3 expression, promoting myeloid-derived suppressor cell migration to the tumor microenvironment and resulting in anti-PD-1 resistance. Enforced Irf2 expression can overcome this resistance [1]. In CD8+ T cells, deletion of Irf2 prevents T cell exhaustion within the tumor, enabling sustained effector functions and enhancing responsiveness to immune checkpoint and adoptive cell therapies [2]. In osteosarcoma, Irf2 negatively correlates with karyopherin alpha 2 (KPNA2). Irf2 binds to the KPNA2 promoter to modulate the malignant phenotypes of osteosarcoma cells [3]. For NK cells, knockdown of Irf2 greatly reduces the cell numbers of all early differentiation stages and impairs functional maturation [5]. In the context of myocardial infarction, IRF2 upregulation mediates gasdermin-D (GSDMD) induced pyroptosis [7]. Also, IRF2 is essential for GSDMD transcriptional activation, and its deficiency attenuates GSDMD expression, IL-1β secretion, and pyroptosis [8]. In melanomas, loss of Irf2 reduces MHC I pathway transcripts and causes resistance to checkpoint immunotherapy, but this can be reversed by interferon-induced IRF1 expression [9].
In conclusion, Irf2 has a wide-ranging impact on biological processes, especially in the immune system and in various diseases. Gene knockout or knockdown models in different cell types and animal models, such as mouse models, have been crucial in revealing its role in immune evasion, tumor development, cell differentiation, and pyroptosis-related pathologies. These findings provide potential targets for enhancing cancer control and treating other diseases like myocardial infarction.
References:
1. Liao, Wenting, Overman, Michael J, Boutin, Adam T, Wang, Y Alan, DePinho, Ronald A. 2019. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. In Cancer cell, 35, 559-572.e7. doi:10.1016/j.ccell.2019.02.008. https://pubmed.ncbi.nlm.nih.gov/30905761/
2. Lukhele, Sabelo, Rabbo, Diala Abd, Guo, Mengdi, McGaha, Tracy L, Brooks, David G. 2022. The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity. In Immunity, 55, 2369-2385.e10. doi:10.1016/j.immuni.2022.10.020. https://pubmed.ncbi.nlm.nih.gov/36370712/
3. Xia, Shuchi, Ma, Yiqun. 2022. IRF2 Destabilizes Oncogenic KPNA2 to Modulate the Development of Osteosarcoma. In Journal of oncology, 2022, 9973519. doi:10.1155/2022/9973519. https://pubmed.ncbi.nlm.nih.gov/36199790/
4. Kim, Inyoung, Kim, Jung Ha, Kim, Kabsun, Lee, Keun-Bae, Kim, Nacksung. . IRF2 enhances RANKL-induced osteoclast differentiation via regulating NF-κB/NFATc1 signaling. In BMB reports, 54, 482-487. doi:. https://pubmed.ncbi.nlm.nih.gov/34488926/
5. Persyn, Eva, Wahlen, Sigrid, Kiekens, Laura, Van Vlierberghe, Pieter, Leclercq, Georges. 2022. IRF2 is required for development and functional maturation of human NK cells. In Frontiers in immunology, 13, 1038821. doi:10.3389/fimmu.2022.1038821. https://pubmed.ncbi.nlm.nih.gov/36544762/
6. Sheikh, Amania A, Utzschneider, Daniel T. . IRF2 integrates inflammatory signals to balance T cell exhaustion. In Immunity, 55, 2225-2227. doi:10.1016/j.immuni.2022.11.010. https://pubmed.ncbi.nlm.nih.gov/36516816/
7. Li, Yongxing, Wang, Yan, Guo, Hua, Wu, Qinghua, Hu, Yamin. 2021. IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis. In Molecular medicine reports, 25, . doi:10.3892/mmr.2021.12556. https://pubmed.ncbi.nlm.nih.gov/34878155/
8. Kayagaki, Nobuhiko, Lee, Bettina L, Stowe, Irma B, Bertram, Edward M, Dixit, Vishva M. 2019. IRF2 transcriptionally induces GSDMD expression for pyroptosis. In Science signaling, 12, . doi:10.1126/scisignal.aax4917. https://pubmed.ncbi.nlm.nih.gov/31113851/
9. Sari, G, Dhatchinamoorthy, K, Orellano-Ariza, L, Brehm, M A, Rock, K. 2024. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas. In Journal of experimental & clinical cancer research : CR, 43, 276. doi:10.1186/s13046-024-03187-5. https://pubmed.ncbi.nlm.nih.gov/39354629/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
